Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

NARecruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Type 2 Diabetic PatientsT2DM (Type 2 Diabetes Mellitus)T2DM
Interventions
DRUG

Beinaglutide

Beinaglutide (continuous subcutaneous infusion)

DRUG

Insulin aspart

Insulin aspart (CSII)

Trial Locations (16)

100034

RECRUITING

First Hospital of Peking University, Beijing

150030

RECRUITING

Heilongjiang provincial hospital, Harbin

450003

RECRUITING

Henan People's Hospital, Zhengzhou

000

RECRUITING

Pinggu District Hospital, Beijing

RECRUITING

Southern Medical University Nanfang Hospital, Guangzhou

RECRUITING

Southeast University Zhongda Hospital, Nanjing

RECRUITING

Xi'an Jiaotong University Second Hospital, Xi'an

RECRUITING

Southwest Medical University Affiliated Hospital, Luzhou

Unknown

RECRUITING

Capital Medical University Beijing Anzhen Hospital, Beijing

RECRUITING

Emergency General Hospital, Beijing

RECRUITING

Peking University Shougang Hospital, Beijing

RECRUITING

Harbin Medical University Second Hospital, Harbin

RECRUITING

Xuzhou Medical University Affiliated Hospital, Xuzhou

RECRUITING

China-Japan Union Hospital of Jilin University, Changchun

RECRUITING

Jilin University Second Hospital, Changchun

RECRUITING

Peking University Binhai Hospital, Tianjin

All Listed Sponsors
lead

Beijing Hospital

OTHER_GOV